Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer

• Published in: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Vol. 858; no. 1; pp. 287 - 291
• Main Authors: Meleh, Marija, Požlep, Barbara, Mlakar, Anita, Meden-Vrtovec, Helena, Zupančič-Kralj, Lucija
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 15.10.2007; Elsevier Science
• Subjects: Analysis; Analytical, structural and metabolic biochemistry; Biological and medical sciences; Biomarker; Biomarkers, Tumor - blood; Chromatography, Gas - methods; Female; Fundamental and applied biological sciences. Psychology; General pharmacology; High performance liquid chromatography; Humans; Lysophosphatidic acid; Lysophospholipids - blood; Medical sciences; Ovarian cancer; Ovarian Neoplasms - blood; Pharmacology. Drug treatments; Reproducibility of Results; Serum; Tandem mass spectrometry; Tandem mass spectrometry; Biomarker; MRM; Ovarian cancer; R.S.D; Lysophosphatidic acid; Serum; ESI; ESI-MS/MS; GC; LPA; HPLC; High performance liquid chromatography; Biological fluid; Ovary cancer; HPLC chromatography; Biological marker; Phospholipid; Tumoral marker; Malignant tumor; Determination; Complex lipid; Female genital diseases; Ovarian diseases; Mass spectrometry MS/MS; Lysophospholipid; Quantitative analysis
• ISSN: 1570-0232; 1873-376X
• DOI: 10.1016/j.jchromb.2007.08.008

A fast and selective analytical method, used to determine the different lysophosphatidic acid (LPA) species in serum, has been developed and validated. LPA species were quantitatively extracted from serum using methanol–chloroform (2:1, v/v). The proteins were precipitated by this solvent mixture and separated by centrifugation in one step. LPA levels were determined in clear extracts using the HPLC-MS/MS method. The linearity of this method was established in the concentration range between 0.1 and 16 μM for all LPA species with a correlation coefficient greater than 0.99. Recovery of all LPA species determined by the serum, fortified at approximately 1 μM and 2–3 μM, was between 93% and 111% with an average R.S.D. of less than 8%. This method was used to determine LPA in numerous sera of healthy controls, patients with benign ovarian tumours and ovarian cancer at different stages. Significantly higher total LPA levels were determined in the sera of patients with different types of tumours (benign and malignant).